• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 3

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Dispatch from ECNP New Frontiers: Psychedelics (Psychedelic Bulletin #134)

Psychedelics Weekly – More Trouble For Field Trip Health, Ketamine Wellness Centers Abruptly Close, & The Creation of the Psychedelic Medicine PAC

atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights

Psyence Group Announces Cantheon Capital Private Placement

Field Trip Health & Wellness Obtains CCAA Protection

Mindset Pharma To Defend Against Lawsuit Filed By Reunion Neurosciences

Clearmind Medicine Appoints Professor Henry R. Kranzler, M.D., to Scientific Advisory...

BetterLife Closes $1,857,143 of Private Placement

Reunion Neuroscience Files Lawsuit Against Mindset Pharma

BetterLife Files Amended and Restated Offering Document for Offering of Units

Psychedelics Weekly – Drug-Free Digital Trips, The Prevalence of Challenging Experiences,...

PT397 – Vital Psychedelic Conversations

Betterlife Publishes Promising Results from a Study Titled “A Non-Hallucinogenic LSD...

BetterLife Announces Pricing of Proposed Offering of Units

Revive Therapeutics Provides Update From Type C Meeting with FDA for...

1234...202Page 3 of 202

EDITOR PICKS

Dispatch from ECNP New Frontiers: Psychedelics (Psychedelic Bulletin #134)

Psychedelics Weekly – More Trouble For Field Trip Health, Ketamine Wellness...

atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

William Leonard Pickard participating in celebration for Sasha Shulgin’s new book...

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©